26 September 2014 in Clinical Endocrinology
8 August 2018 in European Journal of Nuclear Medicine and Molecular Imaging
1 June 2019 in Clinical Nuclear Medicine
Aim: Combined 68Ga-PSMA-617 PET imaging and 177Lu-PSMA-617 therapy is a precise targeted theranostic approach for patients with metastatic castration-resistant prostate cancer (mCRPC). The purpose of this study was to determine whether pretherapeutic standard uptake value (SUV) in 68Ga-PSMA-617 PET could indicate the effective dose in the main organs and absorbed dose in tumor lesions. Methods: After institutional review board approval and informed consent, 9 patients with mCRPC were recruited and underwent 68Ga-PSMA-617 PET/CT scans. Five patients received 177Lu-PSMA-617 (1.30–1.42 GBq, 35–38.4 mCi) and then underwent serial whole-body planar imaging and SPECT/CT imaging of both thoracic and abdominal regions at 0.5-, 2-, 24-, 48-, and 72-hour time points. The other 4 patients received 177Lu-EB-PSMA-617 (0.80–1.1 GBq, 21.5–30 mCi) and then underwent the same imaging procedures at 2-, 24-, 72-, 120-, and 168-hour time points. The effective dose in the main organs and the absorbed dose in tumor lesions were calculated. Detailed correlations between the pretherapeutic SUV in 68Ga-PSMA-617 PET and effective dose in the main organs as well as absorbed dose in the tumor lesions were analyzed. Results: SUV of 68Ga-PSMA-617 PET was moderately correlated with effective dose in main organs (r = 0.610 for 177Lu-PSMA-617, r = 0.743 for 177Lu-EB-PSMA-617, both P < 0.001). SUV of tumor lesions in 68Ga-PSMA-617 PET had high correlation with those in 177Lu-PSMA-617 (r = 0.915, P < 0.001) and moderate correlation with those in 177Lu-EB-PSMA-617 (r = 0.611, P = 0.002). Conclusions: Pretherapeutic 68Ga-PSMA-617 PET may indicate the dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617. Both the effective dose in main organs and absorbed dose in tumor lesions correlate with SUV of 68Ga-PSMA-617 PET. This relationship may help select appropriate candidates for peptide receptor radionuclide therapy. Further investigations of larger cohorts are needed to confirm these initial findings.
1 January 2018 in Theranostics
Objective: 177Lu-DOTA-EB-TATE is a theranostic agent based on octreotate that uses an Evans blue structure to bind albumin to improve the pharmacokinetics and pharmacodynamics. This pilot study aims to evaluate the efficacy of a single low-dose treatment using 177Lu-DOTA-EB-TATE in patients with advanced neuroendocrine neoplasm (NEN).
13 November 2024 in European Journal of Nuclear Medicine and Molecular Imaging
28 February 2022 in International Journal of Endocrinology
Objectives. To analyze and summarize the effect of SSA treatment on EAS due to p-NETs (EAS-p-NETs). Methods. Thirteen patients with EAS-p-NETs treated with SSAs at our center or described in the literature were included in this study. Clinical characteristics, laboratory data, imaging studies, histopathologic results, the effect of SSA treatment, and the prognosis of these EAS-p-NET patients were evaluated. Results. Four males and 9 females with an average age of 42.9 years were included in the study. The mean duration of follow-up was 38.8±28.2 months. As one of the combined treatment measures, SSAs controlled the levels of ACTH and cortisol in 9 of the 13 patients (69.2). Partial response was observed in 3 patients (23.1), stable disease in 2 patients (15.4), and progressive disease in 6 patients (46.2). The median time to tumor progression was 24 months, and the median overall survival was 61 months. The side effects of SSA treatment included temporary mild abdominal pain, diarrhea, gallstones, and cholecystitis. Conclusions. As a supplemental therapy, SSA treatment led to clinical and biochemical improvement with a good safety profile in patients exhibiting EAS-p-NET with metastasis. However, tumor progression was inhibited by SSA treatment in only a few patients. Combined with other treatments, SSAs may improve the prognosis of patients with EAS-p-NETs.